MTA-SZTE Research Group on Artificial Intelligence
SZTE Publicatio Repozitórium - SZTE - Repository of PublicationsNot a member yet
32192 research outputs found
Sort by
The effect of seasonal changing temperature on blood metabolic indicators in Holstein Friesian cows
No full text
Magánjogi rendszerváltozás és a szerződéskötés evolúciója, különös tekintettel a sablonizálható elektronikus üzleti szerződések szabályozására
Get PDFMetabolikus sebészeti irányelvek – 2025 [Guidance of Metabolic Surgery - 2025]
Get PDFAz elhizas napjainkban vilagszerte sulyos problema, melynek megoldasa multidiszciplinaris feladat, amelyben alapveto szerepet jatszik a metabolikus sebeszet. Hazankban is nehany munkacsoport egyre magasabb szamban vegez testsulycsokkento muteteket. Az elvek egysegesitese, az orszagos regiszter kialakitasa es az egyuttmukodes kialakitasa miatt egy evvel ezelott megalakult a Magyar Sebesz TarsasagSebeszeti Endoszkopos es Robotsebeszeti Szekciojanak reszekent a Metabolikus Sebeszeti Munkacsoport.Az ebben reszt vevok konszenzusa es az aktualis nemzetkozi szakmai ajanlasok alapjan elkeszitett es a hazai helyzethez adaptalt allasfoglalasban az indikacios elvek, a muteti tipusok, ezek javallatai, eredmenyei es lehetseges szovodmenyei, az utogondozas kerdesei, valamint a beavatkozasok biztonsagos vegzesehez szukseges intezmenyi hatter kerult megfogalmazasra, illetve kozlemenyunkben ismertetesre
Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy
Get PDFMavacamten is approved to treat adults with symptomatic obstructive hypertrophic cardiomyopathy (HCM). However, its effects in nonobstructive HCM remain uncertain.We conducted a phase 3, international, double-blind, placebo-controlled, clinical trial to determine whether mavacamten improves functional capacity and patient-reported health status among adults with symptomatic nonobstructive HCM. Patients were randomly assigned in a 1:1 ratio to receive mavacamten (starting at 5 mg per day and adjusted up to a maximum of 15 mg per day on the basis of left ventricular ejection fraction) or placebo (with sham dose adjustment) for 48 weeks. The two primary end points were the change from baseline to week 48 in peak oxygen uptake and in the 23-item Kansas City Cardiomyopathy Questionnaire clinical summary score (KCCQ-CSS; scores range from 0 to 100, with higher scores indicating better health status).We randomly assigned 289 patients to receive mavacamten and 291 to receive placebo. The mean (±SD) age of the patients was 56±15 years, and 46% were women. From baseline to week 48, the least-squares mean change in peak oxygen uptake was 0.52 ml per kilogram of body weight per minute (95% confidence interval [CI], 0.09 to 0.95) in the mavacamten group and 0.05 ml per kilogram per minute (95% CI, -0.38 to 0.47) in the placebo group (between-group difference, 0.47 ml per kilogram per minute; 95% CI, -0.03 to 0.98; P = 0.07). The least-squares mean change in the KCCQ-CSS was 13.1 points (95% CI, 10.7 to 15.5) in the mavacamten group and 10.4 points (95% CI, 8.0 to 12.8) in the placebo group (between-group difference, 2.7 points; 95% CI, -0.1 to 5.6; P = 0.06). Reductions in ejection fraction and interruptions in the trial regimen were more common with mavacamten than with placebo.Among patients with nonobstructive HCM, mavacamten did not result in a significantly greater improvement in peak oxygen uptake or decrease in symptoms than placebo. (Funded by Bristol Myers Squibb; ODYSSEY-HCM ClinicalTrials.gov number, NCT05582395.)
Joint Scientific Conference of the Hungarian Physiological Society, the Hungarian Biophysical Society, the Hungarian Microcirculation and Vascular Biology Society, and the Hungarian Bioinformatics Society [MÉT-MBFT-MMVBT-MABIT 2025. Joint Conference]
No full textReal-World Laboratory Analysis of Molecular Biomarkers in Multiple Sclerosis Centers in Central-Eastern European Countries Covering 107 Million Inhabitants
Get PDFA multicenter molecular biomarker survey was conducted in Multiple Sclerosis (MS) centers across Central-Eastern European countries, encompassing a population of 107 million. Our aim was to provide a "snapshot" for future studies investigating the use of molecular biomarkers in MS. A self-report questionnaire was distributed via email to MS centers in seven Central-Eastern European countries (Croatia, Czech Republic, Poland, Romania, Serbia, Slovakia, and Slovenia) and to four reference centers (two in Austria, one in Germany, and one in Denmark), focusing on cerebrospinal fluid (CSF) analysis and molecular biomarkers in MS. Responding centers routinely request CSF oligoclonal band (OCB) testing in suspected MS cases, although no consensus exists on the number of CSF-restricted bands required to define OCB positivity, either within or between countries. More than half of the surveyed centers in the Czech Republic, Slovakia, Slovenia, and the reference centers request kappa free light chain (κFLC) testing in patients with suspected MS. Neurofilament light chain (NfL) is frequently used as a molecular biomarker for MS in Romania, Slovakia, and the reference centers. In summary, besides the use of CSF-specific OCB there is no consensus among the surveyed countries regarding the use of molecular biomarkers in MS
